Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01774344 · OUTCOME

Overall Survival (OS)

Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma · Source last updated 2020-08-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
days
Interval / dispersion
95% Confidence Interval
Time frame
From randomization (Day 1) of the first subject to end of follow upto 1710 days

What was measured

Overall Survival (OS) was defined as the time from date of randomization (Day 1) to death due to any cause

Groups in this outcome

Placebo

Subjects received placebo matched to regorafenib coated tablets orally every day for 3 weeks followed by 1 week off treatment plus best best supportive care.

Regorafenib 160 mg (BAY73-4506)

Subjects received regorafenib 160 milligram (mg) (4 \* 40 mg coated tablets) orally every day for 3 weeks followed by 1 week off treatment plus BSC.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Placebo194
Regorafenib 160 mg (BAY73-4506)379

Reported measurements

Source class 1
Values in days · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Placebo241196196274Not reported
Regorafenib 160 mg (BAY73-4506)326278278372Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        196
        spread
        196
        upper Limit
        274
        value
        241
      2. group Id
        OG001
        lower Limit
        278
        spread
        278
        upper Limit
        372
        value
        326
denoms
  1. counts
    1. group Id
      OG000
      value
      194
    2. group Id
      OG001
      value
      379
    units
    Participants
description
Overall Survival (OS) was defined as the time from date of randomization (Day 1) to death due to any cause
dispersion Type
95% Confidence Interval
groups
  1. description
    Subjects received placebo matched to regorafenib coated tablets orally every day for 3 weeks followed by 1 week off treatment plus best best supportive care.
    id
    OG000
    title
    Placebo
  2. description
    Subjects received regorafenib 160 milligram (mg) (4 \* 40 mg coated tablets) orally every day for 3 weeks followed by 1 week off treatment plus BSC.
    id
    OG001
    title
    Regorafenib 160 mg (BAY73-4506)
param Type
MEDIAN
reporting Status
POSTED
time Frame
From randomization (Day 1) of the first subject to end of follow upto 1710 days
title
Overall Survival (OS)
type
OTHER_PRE_SPECIFIED
unit Of Measure
days

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice